Glivec (imatinib) CML and GIST Treatment Glivec, CML, and GIST Treatment Information for International Healthcare Professionals Glivec, CML  and GIST Treatment Information for US Residents International Glivec Information from Novartis Oncology Click here to go to Novartis.com Novartis Oncology International Site
International Glivec Information from Novartis Oncology
Ask a question
Haematology and Oncology News from Glivec.com

Our weekly newsletter keeps you informed of the latest haematology and oncology news.

Help us improve Glivec.com.
Please take our short survey.

Print Glivec Information from Novartis Oncology emial

**** Haematology News is a current news service provided by Doctor's Guide®. Novartis accepts no responsibility for and makes no representations or warranties regarding the content of the information presented. ****

Week of May 04, 2008
Week of April 27, 2008
Week of April 20, 2008
Week of April 13, 2008

 

The staff of medical writers at Doctor's Guide® may independently summarize and abstract the most current articles on subjects in oncology from the major peer-reviewed medical publications, such as JAMA, New England Journal of Medicine. In all cases, Doctor's Guide® cites the original sources of its material.


Your patients may have questions about Glivec and its role in GIST and CML treatment. Find out the questions patients most frequently ask.

Read the Glivec (imatinib) Fact Sheet (PDF) for concise information on Glivec, CML, and GIST.

You need Adobe® Reader®, available free from Adobe, to download, view, and print PDF files.


Disclaimer: This is an international website for Glivec (imatinib) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the For US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.



Use of this website is subject to our Terms of Use.
© 2008 Novartis Pharma AG